Daiichi Sankyo Reshuffles Biologics R&D, Adds Corporate Venture Arm
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo will centralize biologics research capabilities and plans to speed early discovery with independent venture arm.